HETE ELISA Kits
HETE (Hydroxyeicosatetraenoic Acid) ELISA Kits are immunoassays designed to detect and quantify various HETE metabolites, such as 5-HETE, 12-HETE, and 15-HETE, in biological samples, including serum, plasma, and tissue lysates. HETEs are bioactive lipid metabolites derived from arachidonic acid through enzymatic pathways, such as lipoxygenase and cytochrome P450. These metabolites are involved in inflammatory responses, cell signaling, and vascular health. Measuring HETE levels is essential in research on inflammation, cancer, cardiovascular disease, and metabolic disorders.
Content
HETE ELISA Kits typically include:
- Microplates pre-coated with specific capture antibodies that recognize HETE metabolites.
- Detection antibodies or enzyme-conjugated HETE analogs, facilitating a competitive binding format where sample HETE competes with the labeled HETE for binding to the antibody.
- Standards and controls to create a standard curve, enabling accurate quantification of HETE across samples.
- Buffers and reagents, including wash, blocking, and substrate solutions, which optimize specificity and sensitivity while reducing background noise.
Applications
HETE ELISA Kits are widely used in:
- Inflammation research: Measuring HETE levels to study their roles in inflammatory pathways and immune responses.
- Cancer studies: Investigating HETE’s involvement in tumor progression, cell proliferation, and angiogenesis.
- Cardiovascular research: Assessing the role of HETE metabolites in vascular function, atherosclerosis, and hypertension.
- Metabolic disorder studies: Examining the impact of HETE in diseases like diabetes and obesity, as these metabolites can influence insulin resistance and lipid metabolism.
HETE ELISA Kits provide a reliable, sensitive method for quantifying HETE metabolites, supporting advancements in understanding inflammatory pathways, disease mechanisms, and potential therapeutic targets.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|